prikaz prve stranice dokumenta Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
  Download
PDF 944.03 KB
Scientific paper - Case study
Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
Journal of Personalized Medicine, 12 (2022), 9; 1415. https://doi.org/10.3390/jpm12091415
Zagorec, Nikola; Klarić, Dragan; Klarić, Marta; Horvatić, Ivica; Šenjug, Petar; Horaček, Matija; Nikić, Jagoda; Galešić Ljubanović, Danica; Galešić, Krešimir

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Zagorec, N., Klarić, D., Klarić, M., Horvatić, I., Šenjug, P., Horaček, M. ... Galešić, K. (2022). Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report. Journal of Personalized Medicine, 12. (9). doi: 10.3390/jpm12091415

Zagorec, Nikola, et al. "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report." Journal of Personalized Medicine, vol. 12, no. 9, 2022. https://doi.org/10.3390/jpm12091415

Zagorec, Nikola, Dragan Klarić, Marta Klarić, Ivica Horvatić, Petar Šenjug, Matija Horaček, Jagoda Nikić, Danica Galešić Ljubanović and Krešimir Galešić. "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report." Journal of Personalized Medicine 12, no. 9 (2022). https://doi.org/10.3390/jpm12091415

Zagorec, N., et al. (2022) 'Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report', Journal of Personalized Medicine, 12(9). doi: 10.3390/jpm12091415

Zagorec N, Klarić D, Klarić M, Horvatić I, Šenjug P, Horaček M, and sur.. Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report. Journal of Personalized Medicine [Internet]. 2022 August 30 [cited 2024 May 06];12(9). doi: 10.3390/jpm12091415

N. Zagorec, et al., "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report", Journal of Personalized Medicine, vol. 12, no. 9, August 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:366035. [Accessed: 06 May 2024]

Metadata
Title (english)Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
AuthorNikola Zagorec
AuthorDragan Klarić
AuthorMarta Klarić
AuthorIvica Horvatić
AuthorPetar Šenjug
AuthorMatija Horaček
AuthorJagoda Nikić
AuthorDanica Galešić Ljubanović
AuthorKrešimir Galešić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Personalized Medicine
Numberingvol. 12, no. 9, 1415
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm12091415
URN:NBNurn:nbn:hr:105:366035
Publication2022-08-30
Document URLhttps://www.mdpi.com/2075-4426/12/9/1415
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-02-10 10:32:44